Is Microalbuminuria an Integrated Risk Marker for Cardiovascular Disease and Insulin Resistance in Both Men and Women?

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 3, 2001, Pages 139-146

  Halimi, Jean Michel ^a   Forhan, Anne ^b   Balkau, Beverley ^b   Novak, Michel ^c   Wilpart, Elsie ^d   Tichet, Jean ^e   Marre, Michel ^f  

^a UNIVERSITÉ DE TOURS   (France)

^b INSERM   (France)

^c Chateauroux Hospital   (France)

^d CES Orléans ^*  (France)

^e IRSA Institut Inter Régional Pour la Santé   (France)

^f BICHAT HOSPITAL   (France)

Author keywords

arterial pressure; cardiovascular risk; gender; inflammation; insulin resistance; microalbuminuria

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADULT; ALBUMINURIA; ALCOHOL DRINKING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; CREATININE; ERYTHROCYTES; ESTROGENS; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; POSTMENOPAUSE; PREVALENCE; RISK FACTORS; SEX FACTORS; SMOKING; TRIGLYCERIDES; WOMEN'S HEALTH;

EID: 0034930907     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800304     Document Type: Article

References (45)

1. Tichet J, Vol S, Hallab M, Caces E, Marre M. Epidemiology of microalbuminuria in a French population J Diab Comp 1994; 8: 174–175.
2. Mimran A, Ribstein J, du Cailar G, Halimi JM. Albuminuria in normals and essential hypertension J Diab Complic 1994; 8: 150–156.
3. Jones SL, Close CF, Mattock MB, Jarrett RJ, Viberti GC. Plasma lipid and coagulation factor concentrations in insulindependent diabetics with microalbuminuria BMJ 1989; 298: 487–490.
4. Redon J, Liao Y, Lozano JV, Miralles A, Baldo E, Cooper RS. Factors related to the presence of microalbuminuria in essentialhypertension Am J Hypertens 1994; 7: 801–807.
5. Basdevant A, Cassuto D, Gibault T, Raison J, Guy-Grand B. Microalbuminuria and body fat distribution in obese subjects Int J Obes Relat Metab Disord 1994; 18: 806–811.
6. Marre M. Microalbuminuria and prevention of renal insufficiency andcardiovascular diseases Am J Hypertens 1998; 11: 884–886.
7. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabeticsubjects Lancet 1988; ii: 530–533.
8. Damsgaard EM, Frœland A, Jœrgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderlypeople BMJ 1990; 300: 297–300.
9. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascularmortality in treated hypertensive men with and without diabetes mellitus.Risk Factor Intervention Study Group Am J Cardiol 1997; 80: 164–169.
10. Kannel WB, Kannel C, Paffenbarger RS Jr., Cupples LA. Heart rate and cardiovascular mortality: The Framingham Study Am Heart J 1987; 113: 1489–1494.
11. Cullen KJ, Stenhouse NS, Wearne KL. Raised haemoglobin and risk of cardiovascular disease Lancet 1981; ii: 1288–1289.
12. Knottnerus JA, Swaen GM, Slangen JJ, Volovics A, Durinck J. Haematologic parameters as risk factors for cardiac infarction,in an occupational health care setting J Clin Epidemiol 1988; 41: 67–74.
13. Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J. Haematocrit: A predictor of cardiovascular mortality? J Intern Med 1993; 234: 493–499.
14. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease. The Framinghamstudy: A 34-year follow-up Am Heart J 1994; 127: 674–682.
15. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights fromthe Framingham Study JAMA 1992; 267: 1253–1256.
16. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events Am J Epidemiol 1992; 136: 59–70.
17. Gerber LM, Shmukler C, Alderman MH. Differences in urinary albumin excretion rate betweennormotensive and hypertensive, white and nonwhite subjects Arch Intern Med 1992; 152: 373–377.
18. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predictscardiovascular risk in hypertension J Hypertens 1996; 14: 223–228.
19. Ribstein J, Halimi JM, du Cailar G, Mimran A. Renal characteristics and effect of angiotensin suppression inoral contraceptive users Hypertension 1999; 33: 90–95.
20. The D.E.S.I.R. study group. An epidemiologic survey from a network of French HealthExamination Centres. D.E.S.I.R. Epidemiologic data on the Insulin ResistanceSyndrome Rev Epidem Sante Publ 1996; 4: 373–375.
21. The Expert Committee on the diagnosis andclassification of diabetes mellitus. Report of theExpert Committee on the diagnosis and classification of diabetes mellitus Diabetes Care 1997; 20: 1183–1196.
22. Couderc R, Legrand A. Bilan lipidique en pratique médicalecourante. Biologiste et Praticien, 105, France, 1996.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cellfunction from fasting plasma glucose and insulin concentrations in man Diabetologia 1985; 28: 412–419.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine Nephron 1976; 16: 31–41.
25. Laurier D, Nguyen PC, Cazelles B, Segond P. Estimation of CHD risk in a French working population using amodified Framingham model. The PCV-METRA Group J Clin Epidemiol 1994; 47: 1353–1364.
26. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essentialhypertension Lancet 1974; i: 1190–1192.
27. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R et al. Microalbuminuria in nondiabetic adults:Relation of blood pressure, body mass index, plasma cholesterol levels, andsmoking: The Gubbio Population Study Arch Intern Med 1998; 158: 1933–1939.
28. Woo J, Cockram CS, Swaminathan R, Lau E, Chan A, Cheung R. Microalbuminuria and other cardiovascular risk factors innondiabetic subjects Int J Cardiol 1992; 37: 345–350.
29. Winocour PH, Harland JO, Millar JP, Laker MF, Alberti KG. Microalbuminuria and associated cardiovascular risk factors inthe community Atherosclerosis 1992; 93: 71–81.
30. Tomura S, Kawada K, Saito K, Lin YL, Endou K, Hirano C et al. Prevalence of microalbuminuria andrelationship to the risk of cardiovascular disease in the Japanesepopulation Am J Nephrol 1999; 19: 13–20.
31. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Atherosclerotic risk factors are increased in clinically healthysubjects with microaluminaria Atherosclerosis 1995; 112: 245–252.
32. Goetz FC, Jacobs DR, Chavers B, Roel J, Yelle M, Sprafka J.M., Risk factors for kidney damage in the adult population of Wadena,Minnesota Am J Epidemiol 1997; 145: 91–102.
33. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A et al. Prevalence and clinical correlates ofmicroalbuminuria in essential hypertension: The MAGIC Study.Microalbuminuria: A Genoa Investigation on Complications Hypertension 1997; 30: 1135–1143.
34. Haffner SM, Stern MP, Gruber MK, Hazuda HP, Mitchell BD, Patterson JK. Microalbuminuria. Potential marker for increased cardiovascularrisk factors in nondiabetic subjects? Arteriosclerosis 1990; 10: 727–731.
35. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients withessential hypertension and microalbuminuria J Hum Hypertens 1995; 9: 827–833.
36. Yudkin JS, Marcovina SM, Foyle WJ, Fernandez M. Lipoprotein(a) is not elevated in non-diabetic microalbuminuricsubjects. A longitudinal study of lipoprotein(a) concentrations andapolipoprotein(a) size isoforms Int J Clin Lab Res 1996; 26: 43–50.
37. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria inessential hypertension Kidney Int 1999; 56 (suppl71):S10–3.
38. Mennen LI, Balkau B, Royer B, Caradec A, Marre M and the D.E.S.I.R. Study Group. Microalbuminuriaand markers of the atherosclerotic process. The D.E.S.I.R. Study Atherosclerosis 2001; 154: 163–169.
39. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulinresistance J Intern Med 1999; 245: 621–625.
40. Mahmud N, O'Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D. Tumour necrosis factor-alpha and microalbuminuria in patientswith inflammatory bowel disease Eur J Gastroenterol Hepatol 1995; 7: 215–219.
41. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance innondiabetic subjects: The insulin resistance atherosclerosis study Diabetes 1998; 47: 793–800.
42. Agewall S, Fagerberg B, Attvall S, Ljungman S, Urbanavicius V, Tengborn L, Wikstrand L. Microalbuminuria, insulin sensitivity and haemostatic factors innon-diabetic treated hypertensive men. Risk Factor Intervention Study Group J Intern Med 1995; 237: 195–203.
43. Bianchi S, Bigazzi R, Quinones Galvan A, Muscelli E, Baldari G, et al Insulin resistance in microalbuminuric hypertension. Sites andmechanisms Hypertension 1995; 26: 789–795.
44. Mimran A, Ribstein J, Du Cailar G. Microalbuminuria in essential hypertension Curr Opin Nephrol Hypertens 1999; 8: 359–363.
45. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen J.S., Urinary albumin excretion. An independent predictor of ischemicheart disease Arterioscler Thromb Vasc Biol 1999; 19: 1992–1997.